Impact de la dose d’afatinib sur la tolérance et l’efficacité en vie réelle chez des patients avec CBNPC avancé EGFR muté
Balázs Halmos(Montefiore Medical Center), Enric Carcereny(Institut Català d'Ornitologia), E. Kim(Harvard University), Ross A. Soo(National University Cancer Institute, Singapore), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Te‐Chun Hsia(China Medical University Hospital), Pascal Foucher(CHU Dijon Bourgogne), Toyoaki Hida(Saitama International Medical Center), M. Ki Lee(New Generation University College), Barbara Melosky(BC Cancer Agency), Angela Märten(Boehringer Ingelheim (United States)), Maximilian J. Hochmair(Karl Landsteiner Society), J. Cadranel(Sorbonne Université), E.H. Tan(National Cancer Centre Singapore)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
|Clinical Cancer Research|2006|589
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565